Michael lp

Company: Doheny Image Reading Center

Job title: Medical Director

Seminars:

Transforming Wet AMD Treatment with Ixo-vec, an Intravitreal Gene Therapy 1:30 pm

Explore the innovative approach of Ixo-vec, which uses the AAV.7m8 capsid to deliver a gene encoding aflibercept, enabling continuous production of the VEGF antagonist after a single intravitreal injection Review the LUNA Phae 2 trial results, demonstrating the safety and efficacy of Ixo-vec in reducing the need for frequent anti-VEGF injections and maintaining visual and…Read more

day: Day Two

Panel Discussion: Comparing Gene Therapy Approaches for Wet AMD: Delivery Methods, Targets, & Therapeutic Potential 3:00 pm

How are intravitreal and subretinal delivery methods impacting treatment precision, effectiveness, and patient experience? What are the implications of targeting VEGF suppression versus complement modulation on efficacy and safety? How can we optimize long-term outcomes by addressing durability, immune response, and safety across different gene therapy approaches?Read more

day: Day Two

Fireside Chat: Early Intervention vs. Monitoring in NPDR: Navigating the Controversy 4:00 pm

Debate the merits of early treatment versus monitoring in non-proliferative diabetic retinopathy (NPDR), considering the potential to alter disease progression and prevent vision-threatening events Examine the significant industry investment in early intervention strategies, such as Genentech’s port delivery systems, and their potential to reduce the incidence of diabetic macular edema (DME) and other complications Analyze…Read more

day: Day One